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End stage renal disease diabetic patients suﬀer from worse clinical outcomes under dialysis-independently of modality. Peritoneal
dialysis oﬀers them the advantages of home therapy while sparing their frail vascular capital and preserving residual renal function.
Other benefits and potential risks deserve discussion. Predialysis intervention with early nephrology referral, patient education, and
multidisciplinary support are recommended. Skilled and updated peritoneal dialysis protocols must be prescribed to assure better
survival. Optimized volume control, glucose-sparing peritoneal dialysis regimens, and elective use of icodextrin are key therapy
strategies. Nutritional evaluation and support, preferential use of low-glucose degradation products solutions, and prescription
of renin-angiotensin-aldosterone system acting drugs should also be part of the panel to improve diabetic care under peritoneal
dialysis.
1. Diabetes Mellitus as a Leading Cause of
End-Stage Renal Disease
End-stage renal disease (ESRD) can be considered a
health epidemic involving considerable human and financial
resources [1, 2]. The number of patients with ESRD is
increasing in the world due to aging populations, longer life
expectancy, increasing access to renal replacement therapies
(RRT), and higher incidence of diabetes mellitus (DM) and
hypertension. Nowadays, dialysis is the dominating therapy
to prevent death from uremia, in large part because donor
kidneys are in short supply, and thus, the survival of these
patients is still a major concern [3]. According to the United
States Renal Data System (USRDS), in 2008, the adjusted
rate of prevalent ESRD cases rose 1.9%, to 1.699 per million
population (pmp), with 547.982 patients under treatment.
The prevalent dialysis population increased 3.6%, reaching
382.343 patients and has grown 34.7% since 2000 [4].
Among these amazing numbers, DM is present as the leading
cause of ESRD in the USA and most other countries. After
a dramatic increase in the incidence rate of ESRD due to
diabetes, peaking in 2006 at 160 pmp, this rate fell 3.2%
and 1.5% in the following two years, reaching 153 pmp in
2008, but still corresponding to 43% of all incident patients
[4].
Although their survival is still much worse than that of
nondiabetic counterparts, mainly because of the preexisting
severely compromised cardiovascular conditions, between
1994–1998 and 1999–2003, the 5-year diabetic patients
survival improved 15.3% in hemodialysis (HD) and 27.1% in
peritoneal dialysis (PD), reaching 29% and 27%, respectively
[4]. In Europe, diabetes as the cause of ESRD averaged
124 pmp. In the cohort 1999–2003, the unadjusted 1-, 2-
and 5-year survival of patients on RRT was 80.8% (95% CI:
80.6–81.0), 69.1% (95% CI: 68.9–69.3), and 46.1% (95% CI:
45.9–46.3), respectively. Survival of incident diabetic patients
either in HD and PD was the lowest and around 30% by 5
years [5].
2. Potential Benefits of Peritoneal
Dialysis in Diabetics
Global benefits of home therapy [6, 7] and mainly slow
sustained ultrafiltration (UF) conferred by PD [8] are
particularly important in diabetic uremic patients. Even
before the dialysis stage, most diabetic patients with ESRD
have multiple cardiovascular and metabolic complications.
Because of the rapid and intermittent removal of solutes
and water and the extracorporeal circulation inherent to
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HD, it can frequently be associated with dialysis-induced
hypotension, coronary ischemia, and arrhythmia [9], pos-
sibly leading to a worsening cardiovascular status in these
patients [10]. A recurrent circulatory stress is postulated as a
cause of important deleterious eﬀects of standard schedules
of HD [11]. On the contrary, PD avoids aggressive fluid
shifts oﬀering a better hemodynamic tolerance. It deserves
to be mentioned that HD-induced myocardial stunning is
identified as a new aspect of cardiovascular disease (CVD)
in chronic kidney disease (CKD) [12, 13], while PD is not
associated with such complications [14]. In addition, the
lack of a need to create an arteriovenous fistula, which
increases cardiac load, accelerating heart failure, may also
be a potential benefit of PD in diabetic patients [10]. The
preservation of the vascular network, usually frail in these
patients, and sparing diabetic patients from the serious
complications of vascular access thrombosis and infections
are certainly underestimated but crucial arguments favoring
PD in diabetics.
PD also protects patients from the HD-induced recurrent
regional ischemia that may lead to increased endotoxin
translocation from the gut. Resultant endotoxemia is associ-
ated with systemic inflammation, markers of malnutrition,
cardiac injury, and reduced survival. Circulating endotox-
emia was most notably documented in those patients with
the highest CVD, and a sharp increase was observed after
initiation of HD [15].
Besides, residual renal function (RRF) loss threatens
patient survival both in HD and PD [16]. Diabetes is also a
risk factor for faster RRF decline [17]. However, PD might
confer more RRF protection [18–22] in this group of risk
patients. Moist et al. showed that the risk of RRF loss was
65% lower in PD patients than in HD [23]. Furthermore,
they showed that the selection of HD as the dialysis modality
and diabetic nephropathy were predictors of RRF loss. Thus,
the approach of “PD first” appears to be a rational way to
maximize the maintenance of RRF in diabetics, while simul-
taneously avoiding instrumenting a frail vascular capital and
exposing patients to the risk of aggressive fluid shifts. On the
other hand, RRF preservation and the consequenced higher
elimination of advanced glycated proteins may overcome the
risk of glucose degradation products (GDP) accumulation as
a deleterious eﬀect of PD in diabetics.
Other potential advantages can still be mentioned. Fewer
episodes of progressive diabetic retinopathy were observed
in the PD patients, also fewer events of hemorrhagic
retinopathy, and this is probably related to a more stable
hemodynamic status and a lack of exposure to heparin. In
a Japanese study that evaluated the progression of retinal
lesions in diabetic patients either on HD or PD treatment,
no patients in the PD group showed worsening of diabetic
retinopathy during a 1-year observation period, compared to
approximately 20% of HD patients [24].
Concerning insulin therapy, the advantages of intraperi-
toneal insulin administration include a higher physiological
eﬀect of insulin in patients with diabetic nephropathy
during continuous ambulatory PD (CAPD) or automated
PD (APD) treatment. Major fluctuations of blood glucose,
hyperinsulinemia, and the formation of insulin antibodies
can beminimized. In the final analysis, a better adjustment of
blood glucose levels results [25]. However, there are pros and
cons of various forms of insulin administration therefore,
this might not be a sound argument for PD by itself.
The reduction in insulin requirement is most pronounced
compared with subcutaneous administration when insulin
is instilled into the empty abdominal cavity, but if insulin is
instilled with dialysis solution, there are losses of activity due
to adsorption to the plastic surface of delivery systems [25].
Besides, bioavailability of intraperitoneal insulin might diﬀer
according to the solution bag used [26]. Importantly, hepatic
subcapsular steatosis may be a complication associated
with intraperitoneal insulin [27]. As part of other general
PD benefits that also address diabetics, further aspects
can be added. PD also allows good hemoglobin targets
maintenance at lower erythropoietin doses, with both clinical
and economic advantages [28]. Patients on PD also have
a lower risk of contracting certain blood-borne diseases,
like hepatitis C, which constitutes another advantage of this
modality. In a report by Pereira and Levey, the prevalence of
antiHCV antibodies in patients on dialysis was significantly
lower in PD than in HD patients [29]. Additionally, PD
is associated with lower rates of delayed graft function
after transplantation [30, 31], possibly due to lower risk
of hypotension and hypervolemia particularly relevant in
diabetic patients prone to hemodynamic intolerance. Table 1
summarizes these general and specific PD benefits in diabetic
patients.
3. Controversy on Survival Data
Despite the substantially equivalent survival in diabetic
patients either on HD or on PD [32] and the good reasons
for initially oﬀering PD to this group, only a small and
decreasing proportion of diabetics receive PD [33, 34]. There
is not any a priori first-choice dialytic treatment modality for
these patients, and the decision to adopt HD or PD should be
made onmedical grounds and, above all, on the wishes of the
individual patients. Whichever the modality, diabetics suﬀer
from further clinical complications. A number of earlier
studies documented varied results, some already beneficial
to PD in diabetic patients in spite of addressing a remote
PD era with less therapy resources, others showing possible
lower benefit from PD regimens in older diabetics [35–
40]. A long-term PD favorable study, which included more
than 400 patients, showed that the best survival occurred
in nondiabetic patients on PD, the survival rate of diabetic
patients on PD was equal to that of nondiabetic patients
on HD, and diabetic patients on HD had the worst survival
rate [10]. Subgroup analysis in specific populations might,
however, alert for lower benefits or even increased mortality
risk in older diabetic patients in PD modality [41].
Vonesh et al. systematically reviewed six large-scale
registry studies and three prospective cohort studies that
compared mortality among ESRD patients receiving HD
versus PD, conducted in the US, Canada, Denmark, and
The Netherlands. Generally, PD was associated with equal
or better survival among nondiabetic patients and younger
diabetic patients in all four countries, while among older
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Table 1: Potential benefits and risks of PD in the treatment of diabetic patients.
General PD benefits Specific PD benefits in diabetics PD risks in diabetics
(1) Home-based continuous therapy (1) Sustained daily ultrafiltration (1) Fluid overload
(2) Advantages in lifestyle
(2) Better preservation of residual renal
function
(2) Aggravated dysregulated
metabolic response to glucose
(3) Avoids vascular access related infections (3) Vascular capital preservation (3) Hyperinsulinemia
(4) Avoids recurrent circulatory stress
(4) Avoids peripheral and coronary steal
syndromes
(4) Central obesity
(5) Avoids myocardial stunning (5) Fewer episodes of hypotension (5) Dyslipidemia
(6) Fewer episodes of blood-borne disease (6) Better blood pressure control (6) Peritoneal albumin losses
(7) More liberal diet (in spite of fluid and
Na restriction)
(7) No need for systemic anticoagulation (7) Peritoneal infection
(8) Control of anemia with lower doses of
erythropoietin
(8) Fewer episodes of progressive
retinopathy
(8) Membrane fast transport status
(9) Lack of pain from needle puncture
(9) Feasibility of elective intraperitoneal
insulin
(10) Lower rate of delayed renal graft
function
diabetic patients, results varied by country. Among older
diabetics, the Canadian and Danish registries found no
diﬀerence in survival between PD and HD, while in the US,
HD was associated with better survival only in diabetics aged
45 and older [42]. A more recent Dutch study reported that
the survival advantage for PD compared with HD patients
decreases over time, with age and in the presence of diabetes
as primary disease [43]. Among 139 diabetic PD patients
studied during a mean followup of 28.2 ± 21.8 months,
Fang et al. found 1-, 2-, 3-, and 5-year patient survival
rates of 91%, 76%, 66%, and 47%, respectively [44]. These
outcomes were better than those reported by USRDS for
incident diabetic PD patients (85.7%, 67.9%, 52.5%, and
26.0%, respectively), and the data reported by CORR (86.4%,
53.6%, and 31.3% at 1-, 3-, and 5-year). Diabetic patients
had a significantly poorer survival rate than did nondiabetics,
both in the group younger than 65 and in those patients
aged 65 or older [44]. Two recent studies also showed higher
mortality and hospitalization rates in diabetic versus non
diabetic PD patients. The presence of more morbidity factors
at starting PD and a higher rate of previous cardiovascular
events in diabetic patients may explain part of this risk
[45, 46]. Added reasons for the reported worse outcome
might be the variations in fluid homeostasis and corporal
composition in diabetic patients, as fluid overload is the
main cause of death in ESRD dialysis patients, and fluid
control is potentially more diﬃcult in PD diabetic patients
[47]. Adjusted therapy is mandatory since results might
diﬀer according to treatment skills and policies. Besides,
diﬀerences of some months of survival might be statistically
significant but not clinically relevant. In fact population-
averaged survival curves comparing adjusted PD and HD
survival for USMedicare patients (1995–2000), showing that
adjusted median life expectancy in HD is 35.1 months and in
PD 33.8 months, are such an example [42].
More recent cohorts safely support PD prescription for
diabetic patients, demonstrating similar long-term patient
survival in both modalities and that DM per se should not
be a barrier to PD [48]. Instead, the higher mortality rate
in diabetic PD patients, in particular among female patients,
was mainly attributable to concurrent morbidity such as
CVD and protein-energy wasting, together with low RRF
[49]. PD is more beneficial as the initial modality of dialysis
for ESRD patients. Older patients with diabetes and patients
without diabetes may switch modality to HD or undergo
kidney transplantation in 1-2 years’ time; long-term PD is
viable in younger patients with diabetes [50].
4. Peritoneal Dialysis Risks in Diabetics
Glucose and insulin homeostasis are altered in CKD patients
even in the early stages of renal disease. Metabolic syndrome
is usually defined as a cluster of risk factors—obesity, high
blood pressure, insulin resistance, and dyslipidemia—that
are involved in development of CKD or are a consequence
of it. It is argued that uremic patients treated with PD have
a higher risk for deregulated metabolic response because of
increased glucose absorption, with hyperglycemia prevalence
greater than 50% comparing to 20% in HD patients [51].
It was also found that metabolic syndrome is a potent risk
marker for adverse CV outcomes in nondiabetic patients on
PD [52]. Notably, 60–80% of glucose-containing PD solution
instilled into the peritoneal cavity is absorbed, corresponding
to daily intake of 100–300 g glucose. This continuous glucose
absorption modulated also by uremic toxicity and factors
related to PD fluid bioincompatibility may indeed lead to
aggravation of hyperglycemia, obesity and hyperlipidemia.
Al these factors trigger the production of reactive oxygen
species (ROS) and induce an inflammatory cascade that
includes blocking insulin action and normal lipoprotein
metabolism as recently revised [53]. Waist circumference
is not a correct parameter to evaluate obesity due to the
presence of the Tenckhoﬀ catheter and potential residual
peritoneal dialysate inside the abdominal cavity; however
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the use of body mass index (BMI) is also a biasing factor.
Increased body mass due mainly to fat has a diﬀerent
prognostic meaning than body mass related to more muscle.
PD patients with a high BMI associated with high muscular
mass seem to have a survival advantage, compared with those
with high BMI but lowmuscular mass that have an enhanced
risk of cardiovascular death [54].
It is well established that PD patients frequently gain
weight (fat mass), especially during the first year of PD
therapy and particularly if they have diabetes or have a high
BMI at initiation. However, several groups have not found
any association between glucose absorption and weight gain.
However the application of icodextrin solution may be a
better option to alleviate excessive fat gain over time for
patients on PD with studies revealing a significantly lower
percentage of fat mass during the first 36 months (P <
0.05) [55]. Factors associated with the higher percentage of
fat mass gain over time on PD were age, diabetes, gender
(female) and nonicodextrin group (all, P < 0.01, generalized
estimating equation). Wang and his/her group also found
that genetic factors play an important role in the accumu-
lation of fat mass in PD patients (uncoupling protein 2
exon 8 insertion/deletion polymorphism) [56]. Concerning
to hyperglycemia diagnosis and glycated hemoglobin levels,
important factors must be mentioned, because deregulation
of sugar levels, associated with glucose-containing solutions,
has important non linear implications for the patients. It
has been documented that after 18 months of followup of
269 nondiabetic PD patients, HbA1c was the significant risk
factor for all-cause mortality after relating variables were
adjusted (HR: 4.114; 95% CI: 1.426–11.872; P = 0.009).
Moreover, high HbA1c (HR: 3.892; 95% CI: 1.273–11.959;
P = 0.026) and lowHbA1c (HR: 1.179; 95%CI: 1.160–1.198;
P = 0.039), with middle HbA1c group as the reference,
also significantly predicted for mortality in these patients
[57]. However, PD patients had lower HbA1c values than
those without CKD with the same average glucose level,
suggesting that HbA1c underestimates the glucose level in
these patients. This underestimation might be secondary to
the use of erythropoietin, meaning that a larger proportion
of circulating erythrocytes have not been around long
enough for suﬃcient glycosylation of hemoglobin. It was
shown that a greater predictive value is achieved with the use
of glycated albumin which measures glycemic control over
the preceding 2 weeks and is not aﬀected by serum albumin
concentrations [58]. Furthermore, PD patients are never
truly fasting because they continuously absorb glucose from
the PD solution. So it is important to consider the limitations
of both HbA1c and home glucose monitoring in PD patients
before one makes therapeutic decisions. However, our goal
is to achieve an HbA1c of <7% [59], taking into account
that strict glycemic control based in such parameter might
be hazardous in individual patients [60].
Blood glucose measurements in patients receiving
icodextrin must be done with a glucose-specific method to
avoid interference by maltose, a metabolite of icodextrin.
Glucose dehydrogenase pyrroloquinoline quinone or
glucose dye oxidoreductase-based methods must not be
used. Results inconsistent with clinical suspicion of hypo-
glycemic coma should be retested with another testing system
[61, 62]. Therapy must also be adjusted according to PD
regimens aiming for glucose sparing prescriptions. Diabetic
patients have a minimal increase in insulin requirement
after initiation of PD per se, but the dosage of insulin
increases markedly after exposure to hypertonic glucose
solution [63]. A study of risk factors for high glucose use
in PD patients showed that patients with DM, high BMI,
and low RRF were more likely to require a high glucose
load for PD therapy, especially during the first 3 years.
After that, DM was the only significant factor associated
with the need for higher glucose load [64]. One of the
implications associated with hyperglycemia is the activation
of the thirst mechanism with problems in managing fluid
balance. Devolder et al. evaluated volume status with mul-
tifrequency bioimpedance (body composition monitoring,
bioimpedance analysis (BIA)) in PD and HD patients
revealing in multivariate models that diabetes and being
under PD are associated with increased extracellular water
(ECW) volume [65]. In turn, fluid overload implies use of
more hypertonic bags negatively impacting glycemic control
and peritoneal integrity, therefore creating a vicious circle. A
baseline fast transport status can also be present in diabetics
which will oblige careful therapy adjustment [66]. Peritoneal
membrane exposed to higher content of GDP present in PD
solutions is impaired by several mechanisms. First, GDP acti-
vates an inflammatory process promoting neoangiogenesis
and consequently fast transport proprieties in the face of a
progressive increase in peritoneal permeability. As a result
of the inflammation, profibrotic factors are generated, such
as transforming growth factor beta, leading to peritoneal
fibrosis and accelerated loss of UF, ultimately leading to
possible technique failure in diabetic patients on PD [10].
It is well known that diabetics have impaired antibacterial
defenses and the risk of dying from an infection increases
with worse glycemic control. It was demonstrated that GDP
rich solutions accelerate leucocyte apoptosis and adversely
aﬀect the peritoneal defense [67]. However, neither peri-
tonitis episodes nor other PD related infections have been
observed to bemore common in diabetic than in nondiabetic
patients [47]. Several articles report, notwithstanding the
risks presented, no diﬀerence in technique survival between
diabetics and nondiabetic dialysis group of patients [49].
Clinicians should however be most concerned about nutri-
tional and volume status of PD diabetic patients, which
impact on patient survival. The etiology of malnutrition
is multifactorial (acidosis, insulin resistance, inflammation,
dialysate protein losses) and delayed gastric emptying
associated with autonomic nervous system dysfunction is
considered to be a significant factor. Dialysate volume in
the peritoneal cavity was initially appointed as having a
negative eﬀect on gastric emptying. But in clinical practice
its removal was not associated with any noticeable improve-
ment. A study designed to estimate the direct influence
of indwelling dialysate in the peritoneal cavity on gastric
emptying, in patients treated with CAPD, determined by
dynamic abdominal scintigraphy have shown no significant
diﬀerences between those with and without indwelling
dialysate. However, gastric emptying is markedly impaired
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in CAPD patients compared to healthy subjects indicating
that other factors are responsible for the development of
gastropathy in these patients, suggesting a gastric motility
test with an empty peritoneal cavity [68]. A recent report,
using an extracellular mass/body cell mass ratio (ECM/BCM
ratio) as a marker of malnutrition, revealed that for every
10% increase of it, the relative risk of death was increased
by about 35%, demonstrating that bioimpedance-derived
enrollment ECM/BCM ratio was an independent predictor
of long-term survival in PD patients [69]. Paniagua and
his group studied the role of N-terminal fragment of B-
type natriuretic peptide (NT-proBNP) as a predictor of
mortality in ESRD patients. Showing that NT-proBNP levels
and ECW/total body water (TBW) were correlated with
several inflammation, malnutrition, and myocardial damage
markers, they proved that NT-proBNP might be an added
reliable predictor of death risk independently of the eﬀect of
dialysis modality [70].
Multifrequency BIA also enabled documenting that ECW
adjusted for height was similar in diabetic and nondiabetic
patients, but the ratio of ECW to TBW was greater for
diabetics [71]. Additionally, a prospective study that evalu-
ated heart failure in long-term PD patients concluded that
diabetes and left ventricular mass and volume index were
significant predictors of new-onset heart failure [72]. On the
other hand the status of peritoneal fast transport, if inad-
equately managed, is also associated with worse outcomes
and diabetes has been associated with a higher proportion
of fast transport status. Icodextrin and APD can adequately
support these patients. However there is concern about
peritoneal protein leak during continuous PD procedure
[73], because although correlated with volume overload
and inflammation, it is largely an independent predictor
of mortality [74]. Increased large-pore protein loss may
reflect the severity of underlying CVD, portending a poor
prognosis for these patients. Peritoneal protein clearance and
not peritoneal membrane transport status predicts survival
in contemporary PD patients [75]. Additionally higher
daily peritoneal protein clearance when initiating PD was
independently associated with peripheral arterial disease, a
possible new marker of systemic endothelial dysfunction
[76]. Last but not least, there are concerns about PD
modality and transplantation outcomes. Analysis of the risk
factors for development of posttransplant DM (PTDM) was
performed with respect to pre-transplant dialysis modality.
A total of 137 (6.8%) patients developed PTDM; 7% in
the HD group and 6.5% in the PD (P = 0.85). In the
multivariate analysis, age, BMI, rejection episodes and use
of tacrolimus were identified as independent risk factors
for its development. Adjusted analysis confirmed that pre-
transplant dialysis modality does not have an impact on
the subsequent development of PTDM [77]. Likewise, PD
prior to simultaneous-pancreas-kidney transplantation is
not associated with increased incidence of intra-abdominal
infection compared to HD [78]. As described, PD may
provide several advantages for diabetic patients, while risks
should also be taken into account to optimize therapy
(Table 1).
5. Strategies to Improve Outcomes
Throughout this paper we have emphasized the importance
of preservation of RRF attending to the advantage in con-
trolling fluid balance and solute clearance, protecting patient
life. This task force should be pursuit both before and after
dialysis induction. Early nephrology referral is an important
measure for improved long-term clinical outcome in type
II diabetics on maintenance PD [79]. Indeed attending an
options class predialysis was associated with more frequent
selection of home dialysis, fewer tunneled HD catheters and
lower mortality risk during the first 90 days of dialysis ther-
apy [80]. Considering the timing of dialysis, there is however
no benefit from an early start. A retrospective analysis of
patients, entering the USRDS database from January 1, 1995
to September 30, 2006 was carried out, sorting patients into
groups by estimated glomerular filtration rate (eGFR) at
dialysis initiation. In this total incident population (n =
896, 546), 99,231 patients had an early dialysis start (eGFR
>15mL/min per 1.73m2) and 113,510 had a late start (eGFR
≤ 5mL/min per 1.73m2). The first group had increased
risk of mortality, while the late start was associated with
reduced risk of mortality [81]. In another study planned
early initiation of dialysis (eGFR was 10.0 to 14.0mL/min)
in patients with stage V CKD in comparison with later
stage (eGFR was 5.0 to 7.0mL/min) was not associated with
an improvement in survival or clinical outcomes. During a
median followup period of 3.59 years, 152 of 404 patients
in the early-start group (37.6%) and 155 of 424 in the late-
start group (36.6%) died (HZ with early initiation, 1.04;
95% CI, 0.83 to 1.30; P = 0.75) [82]. An individualized
strategy leveling indication and risk for dialysis induction
in diabetics is mandatory. Dedicated and multidisciplinary
care is than essential to oﬀer the best treatment and the
adequate control of cardiovascular risk factors: diet, exercise
and weight control. Adequate patient education, and support
with dietitian, podologist, endocrinologist and frequent
monitorization are very important. One of the limitations
is severe visual or functional impairment, necessitating the
involvement of a relative. Experience has demonstrated that
even blind patients can perform the technique properly,
although it might oblige individualized and more prolonged
training. Elective assisted PDmight be considered in patients
with less autodialysis capacity. There are multifactorial
interventions that may additionally improve the survival of
diabetic PD patients.
New PD solutions with low GDP are promising in
reducing the risk of CVD in these patients, by preserving
RRF, optimizing volume control, and possibly reducing local
and systemic inflammation.
A study comparing the use of balance, a neutral pH,
low GDP solution to conventional one, during 12 months,
revealed a lower degree of systemic inflammation. The
Balance group had a superior profile of PD eﬄuent markers
of mesothelial cell mass marker and inflammation [83].
As a glucose sparing policy, the use of 1 bag of
icodextrin or amino-acid (AA) solution daily may reduce
the glucose load by 15–30%. In addition, icodextrin use
was significantly associated with a reduced risk of death
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(HR, 0.40; 95% CI, 0.28 to 0.58; P < 0.001) in a recent
retrospective investigation. AA-containing dialysate has been
used to compensate for a low dietary protein intake but
clinical benefits have not been consistently demonstrated
because these solutions can induce an anabolic response in
malnourished patients on CAPD only if enough calories
are ingested simultaneously. Dialysis solutions containing a
mixture of AAs and glucose in appropriate proportions can
serve as a source of both proteins and calories. Although
the metabolism of intraperitoneal AAs causes the generation
of hydrogen ions and urea, acid-base homeostasis can be
preserved using dialysis solutions with a buﬀer content of
40mmol/L [84]. Additionally, calcium exposure through PD
solution plays a role in the progression of arterial stiﬀness,
which may be related to increased vascular calcification
[85], therefore individualized low calcium solutions should
be prescribed. Most importantly icodextrine has a role in
diabetic patients’ PD treatment: as Paniagua et al. state,
in a study of 12 months, the use of icodextrin allows in
the early phase (6 months), reduction in ambulatory blood
pressure (ABP) and left ventricular end diastolic diameter.
These changes correlated with changes in body fluids. In the
late phase (12 months), a trend towards baseline values in
ABP was seen. It was argued that changes in inferior vena
cava diameter and in low-frequency R-R variability spectral
analysis suggest that icodextrin increases circulating blood
volume and sympathetic tone, probably by accumulation of
icodextrin metabolites in the bloodstream and improvement
in diabetic neuropathy as a result of lower peritoneal glucose
absorption [86].
The benefits of icodextrin use in diabetic patients were
also supported by the same investigators in a prospective,
randomized controlled trial, comparing it with conventional
glucose solutions. These authors showed that icodextrin
significantly reduces ECW volume, thereby leading to a
significant reduction in both systolic and diastolic blood
pressure. Moreover, they demonstrated that icodextrin,
reduces blood glucose concentration, a finding that was
accompanied by a concomitant reduction in insulin dosage.
Furthermore, a particularly finding was that icodextrin
was associated with a delay in the decline of eGFR and
urine volume over a 6-month observation period [87]. So
icodextrin, besides its elective indication in fast transporters,
gathers a group of potential benefits in diabetic PD patients:
increase in UF volume with better blood pressure control;
increase in solute clearance; better glycemic control with
fewer requirements for insulin; and better preservation of
RRF.
A bimodal solution based on the mixing of glucose
(2.6%) and icodextrin (6.8%), during a 4-month prospective
intervention period, showed that net UF and peritoneal
sodium removal during the long dwell was about 2-fold
higher than baseline. Therefore a combined crystalloid and
colloid PD solution might be useful as a glucose-sparing
strategy for volume control in high-transport APD diabetic
patients [88]. Low-GDP solutions also are advocated, if
financial constraints are not superimposed: in vitro and ex
vivo studies clearly support better biocompatibility of these
solutions. Notwithstanding, in the clinical field it was mainly
RRF the parameter that showed to be protected by using
these solutions. In a multicenter approach, 80 patients were
randomized to treatment with a PD fluid containing low
levels of GDP or standard PD fluid for 18 months. Data
revealed a significant diﬀerence in monthly RRF change and
twenty-four-hour urine volume decline, demonstrating a
significant benefit concerning preservation of RRF and urine
volume of using a PD fluid with low GDP levels [89]. The
previously mentioned inflammatory cascade, activated by
GDP is mediated by renin-angiotensin-aldosterone system
(RAAS), constitutively expressed in peritoneal mesothelial
cells, and ROS. So it is postulated that use of angiotensin
converting-enzyme inhibitor (ACEI) or angiotensin II recep-
tor blocker (ARB) helps, not only to preserve RRF in
ESRD patients, but also to maintain peritoneal membrane
integrity longer in PD patients. Thus, these classes of drugs
should be the first choice for antihypertensive therapy [59].
Antioxidants, namely N-acetylcystein, might also support
preservation of peritoneal membrane function by the same
mechanism [50] but need further evidence. Table 2 resumes
strategies that potentially will improve clinical outcomes in
PD diabetic patients.
6. Our Clinical Experience of
PD in Diabetic CKD
In our centre, by carrying out a prospective registry based
study of 432 adult incident patients admitted during 25 years
in a PD university program (11640 months at risk), we com-
pared clinical outcomes of PD treatment on diabetic versus
nondiabetic counterparts. At baseline analyzed groups were
identical concerning mean age, proportion of older patients,
gender, previous RRT and reason for PD; diabetic had lower
RRT vintage (33(15–99) versus 75(23–125) months; P =
0.05). Patient survival was significantly lower in diabetic,
when compared to nondiabetic: 89%, 77%, 67%, 52% versus
93%, 86%, 79%, 71%, at 1, 2, 3, and 4 years, respectively (P <
0.0001). However, technique survival was similar between
diabetic and nondiabetic: 84%, 74%, 66%, 51% versus 87%,
79%, 66%, 57%, at 1, 2, 3, and 4 years, respectively (P = NS).
Our results compare favourably with international reports:
In EDTA registry report 2008 [5], diabetic patient survival
was 73% by 2 years; in the French PD registry diabetic
patients lower three-year patient and technique survival was
reported as 59% and 34%, respectively for patients aged 50–
60 years [90].
On multivariate analysis including in the model diabetes,
older status, PD after HD and PD after transplant, DM
was an independent predictor for patient mortality (HZ 2.3;
CI 1.5–3.7) but not for technique failure (HZ 1.3; CI 0.9–
1.9). A lower proportion of diabetics received a renal graft
during the followup (19% versus 32%; P = 0.016). Among
the reasons for transfer to HD, UF failure/underdialysis was
similar between groups (26% versus 22%, P = NS), a higher
proportion of dropout was observed in diabetic due to loss
of autonomy for the technique (23% versus 5%, P = 0.004).
The global peritonitis rate was similar between the diabetic
and their counterparts: 0.53 versus 0.61 ep./pt.y (P = NS).
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Table 2: Strategies to improve clinical outcomes in PD diabetic patients.
Strategies Practice
(1) Opportune nephrology
referral
More than 3 months before dialysis initiation, ideally when GFR ≤ 30mL/min
(2) Residual renal function
protection
Avoidance of dye studies, nonsteroidal antiinflammatory drugs (including cyclooxygenase-2
inhibitors), aminoglycosides, and extracellular fluid depletion
(3) Control of cardiovascular risk
factors
Diet counseling and promotion of physical activity to avoid obesity; pharmacologic therapy for
hypertension atherogenic dyslipidemia, dysglycemia and prothrombotic state (ACE inhibitors,
AII receptor antagonists, B blockers, statins, and aspirin)
(4) Patient education and
multidisciplinary support
Group discussion and individual consultation (booklets, video, and interview) promotion of
hometherapy and transplantation (both renal and renopancreatic) glycemic control optimization
foot care and peripheral vascular evaluation ophthalmologist followup
PD specific strategies
(5) Skilled volume evaluation
and control
Panel of clinical evaluation (blood pressure, weight, and edemas), biomarker (pro BNP) and
multifrequency BIA (longitudinal trends of body composition) high-dose furosemide fluid, and
sodium restriction elective use of icodextrine and APD
(6) Preferential use of low GDP
solutions, glucose sparing
regimens, and individualized low
calcium solutions
Avoidance of hypertonic bags use Bi/tri compartment bag solutions (low GDP) individualized
low Ca solutions prescription “PEN” regimen: physioneal; extraneal; dianeal; “NEPP” regimen: 1
amino acid exchange, 1 icodextrin exchange, and 2 glucose bicarbonate/lactate exchanges as
options
(7) Nutritional evaluation and
support
Assessed by a panel: subjective global assessment (SGA), protein equivalent of nitrogen
appearance (nPNA), serum albumin and lipid profile, multifrequency BIA diet counseling by
nutritionist
Enteric supplements (protifar as protein supplement) peritoneal supplement (nutrineal once day)
(8) Preferential use of RAAS
acting drugs
ACEI and ARB as first antihypertensive drugs possible protective eﬀects in peritoneal membrane
status
(9) Optimize technique survival
and opportune transfer to HD
International recommendations on peritoneal access management and prophylactic measures
individualized training and retraining peritonitis rate systematic control and quality assessment
individualized APD prescription depression assessment and specific management routine annual
peritoneal membrane evaluation
The global hospitalization rate was significantly higher in
diabetics than in nondiabetics: 1.39 versus 0.84 ep./pt.y (P =
0.004). In our study, PD proved to be an eﬀective long term
RRT option in diabetics, without a higher rate of technique
failure, UF failure or peritonitis. DM was however associated
with higher mortality, higher autonomy loss, and higher
hospitalization rate, enhancing the need for investigation and
control of comorbidities with potential negative impact on
these parameters.
7. Conclusion
Diabetes is among nephrological causes of ESRD that are
associated with the worst diagnosis. Independently of the
renal replacement therapy patient survival is limited and
exposed to higher rate of complications and hospitalizations.
PD however, oﬀers a cluster of advantages in diabetic
patients: besides amenable better life-style the modality
avoids vascular access complications in patients with frail
vascular capital, protects RRF, and allows higher hemody-
namic stability with less myocardial stress and stunning,
with slower progressive retinopathy. The disadvantages can
be overcome by adequate care, glucose-sparing PD regimens,
optimization of volume control and other protective mea-
sures like RAAS acting drugs and antioxidants to prolong the
best quality of care while on PD. P. Cotovio and A. Rocha
contributed equally to this paper.
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